Hi there, A few hours ago, you requested to receive a free copy of MarketBeat's latest report, "7 Stocks to Buy And Hold Forever." I noticed that you hadn't opened the email we sent with your free report, so I just wanted to follow up and make sure you received it. If you missed the initial message, you can access your free report directly by clicking the link below: Download your report here (PDF). If you have any trouble accessing the report, please don't hesitate to reach out to our support team by replying to this message. Thanks, Jessica Mitacek
Managing Editor
MarketBeat
Further Reading from MarketBeat Media Hinge Health's AI Moat Might Be Its Patient Movement DataWritten by Leo Miller. Date Posted: 2/23/2026. 
Key Points - PwC expects medical cost inflation to remain elevated, which strengthens the appeal of cost-reduction platforms like Hinge Health.
- Hinge’s MSK model is built to reduce therapy intensity and potentially avoid costly surgeries, supporting insurer adoption.
- Strong results are tempered by elevated stock-based compensation, though management expects SBC to normalize.
- Special Report: [Sponsorship-Ad-6-Format3]
The cost of healthcare in the United States is rising sharply. In its 2026 healthcare outlook, the Big Four accounting firm PricewaterhouseCoopers (PwC) emphasized this trend. "The US healthcare system is heading into another year of powerful inflationary forces exerting pressure, with few deflationary forces in sight." PwC estimates that group insurance medical costs rose 8.5% in 2024—the fastest pace since 2012—rose another 8.5% in 2025, and expects roughly the same pace in 2026. In this environment, Hinge Health (NYSE: HNGE), a mid-cap healthcare stock, is an interesting contender. Hinge's business model focuses on lowering healthcare costs, and some of the industry's largest players are taking notice. Below we break down this fast-growing firm and assess its outlook after an impressive earnings report. Understanding HNGE: Lowering Musculoskeletal Costs in Healthcare Hinge Health targets one costly segment of healthcare: musculoskeletal (MSK) care. Its virtual MSK therapy platform delivers personalized physical therapy programs patients can do at home via a mobile app, wearable devices, AI coaching and human support teams. Hinge says that in 2024 its platform reduced the human hours required to support patients by roughly 95% compared with traditional physical therapy. Cutting human hours helps lower costs, which is a primary reason insurers and employers contract with Hinge. The biggest cost driver for MSK conditions is surgery. Hinge contends that consistent, lower-friction intervention through its platform reduces the likelihood patients will eventually need surgery. Patients may find it easier to follow Hinge's at-home program than to schedule and travel to in-person appointments, and greater adherence can translate into fewer surgeries and savings for insurers. One study looked at nearly 7,000 patients—about half using Hinge and half receiving traditional care—and found the incidence of spinal fusion surgeries among Hinge users was 56% lower than in the comparison group. Insurers are taking notice. Hinge now works with more than 2,800 self-insured corporations, including 45% of Fortune 500 companies. The company is also integrated with the U.S.'s five largest health plans, including UnitedHealth Group (NYSE: UNH), and with the three largest pharmacy benefit managers—making it easier for new employers and members to join the platform. Hinge Soars After Latest Earnings Report, But SBC Is Elevated In its latest quarter, Hinge reported revenue of $171 million, up 46% year over year. Adjusted earnings per share rose 23% to $0.49, both figures beating estimates and sending the stock up about 17%. For 2026, the company projects full-year revenue growth of 25%, a meaningful deceleration from 2025's 51% growth, while expecting adjusted operating margin to increase slightly from 20% to 21%. Free cash flow in 2025 surged to $180 million, a roughly 300% increase versus 2024. A major caveat to that free cash flow figure is stock-based compensation (SBC). SBC is a non-cash expense, but if employees were paid in cash instead of equity, the company would need significant cash outlays. Large SBC can therefore make reported free cash flow look stronger than it would be under cash compensation. Hinge's SBC expense totaled $643 million—more than three times the free cash flow it generated. On a positive note, Hinge says SBC should fall substantially. It expects SBC to average roughly $20 million to $25 million per quarter over the next four to eight quarters. HNGE: An Intriguing AI Play on Healthcare The MarketBeat consensus price target on Hinge Health sits near $57, implying about 35% upside from current levels. Price targets updated after the company's earnings are modestly lower, averaging around $55, which would imply roughly 31% upside. Hinge's model is gaining traction with insurers, and the company may have a defensible position against AI competition. It collects proprietary data from patients' workouts and interactions with its AI assistant—movement-based data that's costly and time-consuming for competitors to replicate at scale. The stock trades at a forward price-to-earnings ratio near 21x, which is not overly expensive. Still, with a market capitalization under $4 billion and investors cautious about software names, Hinge could experience significant volatility despite its promising fundamentals.
| 
Post a Comment
Post a Comment